132 related articles for article (PubMed ID: 15093948)
1. Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives.
Shimazu S; Miklya I
Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):421-7. PubMed ID: 15093948
[TBL] [Abstract][Full Text] [Related]
2. The use of the synthetic enhancer substances (-)-deprenyl and (-)-BPAP in major depression.
Gaszner P; Miklya I
Neuropsychopharmacol Hung; 2004 Dec; 6(4):210-20. PubMed ID: 15825677
[TBL] [Abstract][Full Text] [Related]
3. Major depression and the synthetic enhancer substances, (-)-deprenyl and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane.
Gaszner P; Miklya I
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jan; 30(1):5-14. PubMed ID: 16023777
[TBL] [Abstract][Full Text] [Related]
4. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
Miklya I
Neuropsychopharmacol Hung; 2008 Mar; 10(1):15-22. PubMed ID: 18771016
[TBL] [Abstract][Full Text] [Related]
5. The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).
Miklya I
Mol Psychiatry; 2016 Nov; 21(11):1499-1503. PubMed ID: 27480491
[TBL] [Abstract][Full Text] [Related]
6. (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
Knoll J; Yoneda F; Knoll B; Ohde H; Miklya I
Br J Pharmacol; 1999 Dec; 128(8):1723-32. PubMed ID: 10588928
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
Yoneda F; Moto T; Sakae M; Ohde H; Knoll B; Miklya I; Knoll J
Bioorg Med Chem; 2001 May; 9(5):1197-212. PubMed ID: 11377178
[TBL] [Abstract][Full Text] [Related]
8. A longevity study with enhancer substances (selegiline, BPAP) detected an unknown tumor-manifestation-suppressing regulation in rat brain.
Knoll J; Baghy K; Eckhardt S; Ferdinandy P; Garami M; Harsing LG; Hauser P; Mervai Z; Pocza T; Schaff Z; Schuler D; Miklya I
Life Sci; 2017 Aug; 182():57-64. PubMed ID: 28623006
[TBL] [Abstract][Full Text] [Related]
9. 1-(Benzofuran-2-yl)-2-(3,3,3-trifluoropropyl)aminopentane HCl, 3-F-BPAP, antagonizes the enhancer effect of (-)-BPAP in the shuttle box and leaves the effect of (-)-deprenyl unchanged.
Knoll J; Miklya I; Knoll B; Yasusa T; Shimazu S; Yoneda F
Life Sci; 2002 Sep; 71(17):1975-84. PubMed ID: 12175892
[TBL] [Abstract][Full Text] [Related]
10. Longevity study with low doses of selegiline/(-)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP).
Knoll J; Miklya I
Life Sci; 2016 Dec; 167():32-38. PubMed ID: 27777099
[TBL] [Abstract][Full Text] [Related]
11. [Slowing the age-induced decline of brain function with prophylactic use of (-)-deprenyl (Selegiline, Jumex). Current international view and conclusions 25 years after the Knoll's proposal].
Miklya I
Neuropsychopharmacol Hung; 2009 Dec; 11(4):217-25. PubMed ID: 20150659
[TBL] [Abstract][Full Text] [Related]
12. Treatment possibilities of Alzheimer's disease.
Miklya I; Gaszner P
Neuropsychopharmacol Hung; 2004 Dec; 6(4):200-9. PubMed ID: 15825676
[TBL] [Abstract][Full Text] [Related]
13. A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study.
Miklya I; Knoll B; Knoll J
Life Sci; 2003 Apr; 72(23):2641-8. PubMed ID: 12672509
[TBL] [Abstract][Full Text] [Related]
14. Cytoprotective effect of two synthetic enhancer substances, (-)-BPAP and (-)-deprenyl, on human brain capillary endothelial cells and rat PC12 cells.
Denes L; Szilágyi G; Gál A; Bori Z; Nagy Z
Life Sci; 2006 Aug; 79(11):1034-9. PubMed ID: 16624331
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
16. (-)Deprenyl (Selegiline): past, present and future.
Knoll J
Neurobiology (Bp); 2000; 8(2):179-99. PubMed ID: 11061214
[TBL] [Abstract][Full Text] [Related]
17. Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives.
Knoll J
Neurochem Res; 2003 Aug; 28(8):1275-97. PubMed ID: 12834268
[TBL] [Abstract][Full Text] [Related]
18. Enhancer substances: selegiline and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane [(-)-BPAP] enhance the neurotrophic factor synthesis on cultured mouse astrocytes.
Shimazu S; Tanigawa A; Sato N; Yoneda F; Hayashi K; Knoll J
Life Sci; 2003 May; 72(24):2785-92. PubMed ID: 12679194
[TBL] [Abstract][Full Text] [Related]
19. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Fernandez HH; Chen JJ
Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
[TBL] [Abstract][Full Text] [Related]
20. Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain.
Knoll J
CNS Drug Rev; 2001; 7(3):317-45. PubMed ID: 11607046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
